2 weeks Ago By Defense World Staff
American Century Companies Inc. lifted its position in shares of Qiagen ( NYSE:QGEN – Free Report ) by 34.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The firm owned 31,904 shares of the company’s stock after purchasing an additional 8,130 shares during the quarter. American Century Companies Inc.’s holdings in Qiagen were worth $1,311,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC grew its position in shares of Qiagen by 396.6% during the 2nd quarter.
Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after acquiring an additional 2,189 shares during the period. Oak Thistle LLC grew its holdings in Qiagen by 47.9% in the second quarter.
Oak Thistle LLC now owns 20,663 shares of the company’s stock valued at $849,000 after purchasing an additional 6,695 shares during the period. Acadian Asset Management LLC increased its position in shares of Qiagen by 6.1% in the second quarter.
Acadian Asset Management LLC now owns 48,267 shares of the company’s stock valued at $1,992,000 after buying an additional 2,796 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Qiagen by 104,759.
6% during the 2nd quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock worth $65,061,000 after buying an additional 1,581,870 shares during the period.
Finally, TD Asset Management Inc purchased a new position in shares of Qiagen during the 2nd quarter valued at approximately $2,103,000. 70.00% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $52.
00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Robert W.
Baird boosted their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd.
Finally, Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Thursday, June 27th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock.
According to data from MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and an average price target of $50.25.
Qiagen Stock Up 0.7 % QGEN stock opened at $45.56 on Tuesday.
The company has a market cap of $10.40 billion, a price-to-earnings ratio of 30.55, a PEG ratio of 3.
20 and a beta of 0.39. The firm has a 50-day moving average of $45.
26 and a two-hundred day moving average of $43.49. Qiagen has a 12 month low of $34.
74 and a 12 month high of $47.44. The company has a current ratio of 1.
77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.
Qiagen ( NYSE:QGEN – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.
52 by $0.03. The firm had revenue of $496.
00 million for the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a return on equity of 12.
92% and a net margin of 3.75%. The firm’s revenue was down .
2% compared to the same quarter last year. During the same quarter last year, the business posted $0.53 earnings per share.
As a group, analysts forecast that Qiagen will post 2.15 earnings per share for the current fiscal year. Qiagen Profile ( Free Report ) QIAGEN N.
V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles Five stocks we like better than Qiagen What Makes a Stock a Good Dividend Stock? TJX Stock: A Buying Opportunity Before the Holiday Rush 2 Fintech Stocks to Buy Now and 1 to Avoid Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge P/E Ratio Calculation: How to Assess Stocks Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen ( NYSE:QGEN – Free Report ). Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.
com's FREE daily email newsletter ..
